Release Date: 07-Feb-2023
Oncolytic viruses are one of the most recently emerging therapeutic methods for cancer treatment. These viruses have an affinity for tumor cells and this characteristic is being widely exploited in the cancer therapy domain, confirming its potential in the future for shaping the treatment plans for cancer. The increasing curiosity and studies on oncolytic viruses has expanded the clinical pipeline and allowed the progression of some candidates from preclinical to clinical trials, with some of these getting regulatory approvals. The commercial performance of this unique therapeutic approach has helped grabbed the attention of many and it is anticipated that some current candidates in the clinical pipeline will get approval in the coming years
Download Global Oncolytic Virus Immunotherapy Market and Clinical Trials Insight 2028 Report
Existing cancer therapies have shown success but limited potential in terms of balancing their benefits while maintaining the patient’s quality of life. With advancements in science and technology, oncolytic viruses have come into focus for their innate ability to target cancer cells. This is expected to further broaden and advance the therapeutic landscape of the current cancer treatment scenario. In spite of the limitations faced previously, newer clinical trials have seen the entry of genetically modified oncolytic viruses with superior properties, which have helped developed of oncolytic virus therapies pick up pace.
Clinical trials for currently available oncolytic virus therapy have shown robust anti-tumor immunity characterizing the remarkable and long term responses observed in the patients. The data has suggested that the future of oncolytic virus therapy can be enhanced with incorporation with other strategies which will maximize the immunotherapeutic potential of this approach. A phase II clinical trial on oncolytic herpes simplex virus (HSV) Talimogene laherparepvec (T-VEC) has demonstrated a 16.3% durable response rate and a 5 year survival rate for patients with advanced melanoma suggesting a successful induction of antiviral immunity.
Similar to existing immunotherapeutic approaches, the combination of oncolytic viruses is being tested with immune checkpoint inhibitors which have proven to be one of the most utilized immunotherapeutic approaches. RT-01 is an oncolytic virus injection currently in its phase I trial being tested in combination with Nivolumab which is a monoclonal antibody targeting the PD-1 immune checkpoint. Immune checkpoint inhibitors have proven their use over the years with exponential benefits and efficacy that their combinational use with another promising approach like oncolytic viruses is being highly anticipated with even more benefits and increased use for a wide range of patients.
Companies over the world have started to recognize this approach’s potential and have started vigorously investing into it. A California based biotech firm Genelux, which has been developing oncolytic viral immunotherapies has reached a milestone in their clinical phase trials. The company’s lead candidate Olvi-Vec, a modified strain of the vaccinia virus, has met a pre-established endpoint in phase II trials for patients with platinum-resistant/refractory ovarian cancer. Now, phase III trials for the drug candidate have begun which was officially launched during the second quarter of 2022 and began its enrollment during the 3rd quarter.
With the increasing popularity in oncolytic virus therapy and oncolytic virus based immunotherapy, collaborations and partnerships between companies have been reportedly swelling as well. The accelerated research and development for this approach has resulted in enhanced outcomes leading to the quick entry of potential candidates in clinical phase trials to a quicker entry into the commercial market. The different potential use of the immunomodulatory genes of the viruses is a strategy gaining the most momentum which can further reduce systemic side effects caused during conventional therapies.
Our report aims to explore the emerging market of oncolytic virus based therapy and its potential combinational use with immunotherapy. The report focuses on the existing drugs and medications based on oncolytic viruses, their patent, price, dosage and sales analysis with extensive research done on the candidates that are being tested for their expected use and are in clinical phase trials. The report will give a descriptive view on the current market scenario and the future impact the approach might have on the market.
Oncolytic virus therapy, oncolytic viruses, virotherapy, virus immunotherapy, market for oncolytic viruses, future market outlook for oncolytic viruses, current market scenario, clinical trials, company collaborations,